Compare OM & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OM | MDAI |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.2M | 48.0M |
| IPO Year | 2020 | 2021 |
| Metric | OM | MDAI |
|---|---|---|
| Price | $2.82 | $1.06 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.67 | $5.11 |
| AVG Volume (30 Days) | 82.8K | ★ 135.6K |
| Earning Date | 11-04-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.88 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,476,000.00 | $19,650,000.00 |
| Revenue This Year | $6.72 | N/A |
| Revenue Next Year | $9.25 | $74.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.09 | N/A |
| 52 Week Low | $2.84 | $1.18 |
| 52 Week High | $6.49 | $2.97 |
| Indicator | OM | MDAI |
|---|---|---|
| Relative Strength Index (RSI) | 27.40 | 23.00 |
| Support Level | N/A | N/A |
| Resistance Level | $3.31 | $1.72 |
| Average True Range (ATR) | 0.30 | 0.12 |
| MACD | -0.16 | -0.03 |
| Stochastic Oscillator | 3.47 | 3.43 |
Outset Medical Inc is a medical technology company pioneering a technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.